



Covid-19 vaccine candidate:

Novasep signs a Master Supply and Development Agreement with AstraZeneca

Lyon, France – 12 November, 2020 - Novasep, a leading supplier of services and technologies for the life sciences industry, is pleased to announce that it has now signed a multi-year Master Supply and Development Agreement with AstraZeneca to support large-scale production of the active substance of the adenovirus vector-based COVID-19 vaccine candidate, AZD1222.

This new contract follows the initial agreement signed between AstraZeneca and Novasep Belgium on June 14th in the context of the Inclusive Alliance for Vaccines (IAV), whose members are France, Germany, Italy and the Netherlands.

The production of the vaccine candidate active substance under this supply agreement will be carried out at Novasep's site located in Seneffe, Belgium which expects to increase its workforce from 280 to close to 400 by 2021 to support this project.

Novasep brings to AstraZeneca more than 20 years of expertise in viral vector production in addition to its recent investments enabling the large-scale production of biopharmaceutical products for immunotherapy and gene therapy.

Dr. Michel Spagnol, Chairman & CEO of Novasep Group, comments: « This new agreement once again attests to our clients' confidence in our expertise and demonstrates the commitment and recognised know-how of our teams mobilised on site for this crucial project to fight the COVID-19 pandemic. »

About Novasep

Novasep provides cost-effective and sustainable manufacturing solutions for the life sciences industries.

With 20 years' experience in the development and manufacturing of biomolecules, Novasep offers a full range of CDMO services for:

- [Viral vectors](#) (AAV, Adenovirus, Lentivirus, HSV, VSV, VEEV...) for cell and gene therapy, immunotherapy and vaccination, from process development to cGMP production
- [Fill & Finish](#) services for viral vectors, attenuated and live viruses, mAbs, plasmids and other biologics, from formulation to packaging

As part of its growth strategy Rise-2, Novasep recently unveiled a new facility, [Senrise-IV](#), dedicated to the commercial production of viral vectors which has been completed last year by [Senefill](#), a new Fill & Finish commercial facility for aseptic operations. Both facilities located in Seneffe, Belgium, will contribute to the success of biopharmaceutical projects.

Contact presse

Brunswick Group
Agnès Catineau / Oriane Bornand / Solène Deguet
Novasep@brunswickgroup.com
+33 7 78 50 95 46